


The *Art* and **SCIENCE**
of Integrated Pharmacy Practice

藥劑服務的 **藝術** 與 **科學**



HONG KONG
PHARMACY
CONFERENCE

香港藥劑學術年會

2016 27-28 FEBRUARY
HK Convention & Exhibition Centre



CUHK



DH



HA



HKU



PSHK



PPA



SHPHK

The Art and Science of Integrated Pharmacy Practice

This is a crucial moment for the pharmacy profession in Hong Kong as it strives to elevate its standard of practice. By continuously integrating the latest advances in science and technology with the current thinking in public health, the public stands to benefit from a re-invigorated pharmacy profession that is knowledgeable and skilled in assuring the public's access to effective and safe medicine at an affordable price. The attainment of this goal is facilitated by the convergence of powerful external forces that have relentlessly been shaking the very foundation of the aging Hong Kong healthcare system. Visionary and courageous leadership is required to build a new system that is robust, efficient, collaborative, and patient-centric. The 2016 Hong Kong Pharmacy Conference will highlight the game changing scientific and technological advances with the potential to transform therapeutics and to enable pharmacists to develop entrepreneurial roles in serving the patient. This is the essence of the conference theme, "The Art and Science of Integrated Pharmacy Practice."

In the decade since the completion of the Human Genome Project in April 2003, advances in life science research have dramatically refined our molecular understanding of complex diseases such as cancer and obesity, shifted drug development of late in favor of biologics and vaccines, and diversified the repertoire of tools to identify the likely responders to innovative, lifesaving medicine. Wearable technologies based on smart phones and smart watches will help in improving adherence of patients to the dosing regimen their doctors have prescribed. The behavioral information of the patient's motivation towards adherence, coupled with their unique genetic and personal data and medical history, will contribute to Big Data across the sampling population – believed to be an indispensable resource in future new drug development as well as creation of entrepreneurial pharmacy services.


A major challenge in contemporary therapeutics from the pharmacist's (and patient's) perspective is the exorbitant price of the newly minted cancer or orphan drugs, which typically are priced on the order of US\$100,000 per dose or course of therapy. In fact, the international oncologists' community has been very vocal in questioning the justification for the drug price. It is likely that practitioners of other medical specialties will follow suite. Despite the lower profit margin as compared with generics, it is substantial enough to motivate the multinationals to manufacture biosimilars off their competitors' reference product.

There is a growing trend in the advanced economies that many consumers are willing to abandon traditional care venues for more affordable and convenient alternatives. Because of the historical reliance of the public on Hong Kong's open-access government subsidized healthcare system, it will be another decade at the very least for the scenarios of the health care business looking much more like other consumer-oriented, technology-enabled industry.

This then is the context upon which the **framework** of the 2016 Pharmacy Conference is set. Day 1 will be devoted to game changers in the pharmacy profession, hence patient care. Day 2 will cover precision medicine, modified release drug products, biosimilars, vaccines, wearables, next generation gene sequencing, practice research, and drug regulation. For the first time in the history of the Conference, time will be set aside for undergraduate and postgraduate students to make a 3-minute summary presentation of his/her poster, which has been short listed by the Abstract Screening Committee. On this busy Sunday afternoon, the pre-pharmacy council task force intends to update everyone on its progress towards submitting a proposal to the Bureau of Food and Health, requesting support for establishing a Pharmacy Council in Hong Kong.

I hope you'll find the 2016 meeting conference informative and thought provoking. I look forward to greeting you at the conference.

Sincerely yours,



Vincent H.L. Lee
Chairman, Organizing Committee
Hong Kong Pharmacy Conference 2016

HONG KONG
PHARMACY
CONFERENCE

香港藥劑學術年會

2016 27-28 FEBRUARY
HK Convention & Exhibition Centre



CUHK



DH



HA



HKU



PSHK



PPA



SHPHK

Theme Speeches

- Public private partnership
- Entrepreneurship as a 21st century skill for pharmacist
- The skyrocketing prices of modern pharmaceuticals: An opportunity or challenge for pharmacists?
- Immunotherapy in cancer treatment
- Coaching – Modern pharmacy management and development

Lunch Symposium

- Advanced drug treatment in asthma and COPD

Highlights on Concurrent Sessions

I: Dyslipidaemia

- Guidelines stand-off: Treating your patients like Americans or Europeans?
- Statins intolerance – Evidence, mechanism, management. What's more to say?
- PCSK9-targeted agents in an era without treatment targets

II: Emerging Therapeutics

- Next generation sequencing to help drug choice
- Nanotechnology – Advances and applications
- Advanced Parkinson's disease treatment update – Pharmacotherapy and surgical interventions

III: Coaching

- Coaching – Practical exercises, discussion and case examples

IV: Infectious Disease and Practice

- Novel antibiotics in the pipeline and investigational treatment for MERs-CoV
- Role and impact of clinical pharmacist in infectious disease

V: Public Private Interface

- Public-private partnership project of diabetes care
- Public-private partnership with residential care home for the elderly

VI: Biosimilars

- Regulatory and therapeutic prospects of biosimilars
- Commercial, therapeutic and procurement impact of biosimilars

VII: Practice Research


- Practice research – The acceptable practice that brings reliable results
- Big Data: Concept and current development
- Research on medication safety: How could the impact of medicine safety policy and practice be evaluated?

VIII: Drug Formulation and Pharmacokinetics

- A scientific and practical review of modified release formulations – Splittable, breakable, crushable?
- How rigid are dosing intervals and special dietary considerations? Application of PK concepts
- Therapeutic drug monitoring in clinical setting

IX: Advanced Practice

- Medical 3D printing to individualize dosing: The new era that may truly enhance adherence
- The enabler that revolutionizes pharmaceutical research and development and improves drug safety



Programme Rundown

27 February 2016 (Saturday)

Time	Venue	Lecture Theatre, LG1, Ruttonjee Hospital
9:45am - 11:15am		Pre-conference Lecture: Creating Evidence-based Practice from Practice-based Research Professor Grace Kuo, USA
		Room N101 (Level 1, Phase II)
2:30pm – 2:40pm		Opening Ceremony
2:40pm – 2:50pm		Welcome Speech Professor Vincent Lee Chairman Organizing Committee of HKPC 2016
2:50pm – 3:00pm		Keynote Address Professor Tai-fai Fok Pro-Vice-Chancellor The Chinese University of Hong Kong, Hong Kong
3:00pm – 3:30pm		Theme Speech 1: Public Private Partnership Dr. Wai-lun Cheung Director (Cluster Services) Hospital Authority, Hong Kong
3:30pm – 4:00pm		Theme Speech 2: Entrepreneurship as a 21st Century Skill for Pharmacist Professor William Charman Dean Faculty of Pharmacy and Pharmaceutical Sciences Monash Institute of Pharmaceutical Science Monash University, Australia
4:00pm – 4:30pm		Coffee Break - Poster Presentations & Exhibition
4:30pm – 5:00pm		Theme Speech 3 New Trends in Drug Pricing: A Threat or a Promise? Professor Stuart Schweitzer Department of Health Policy and Management UCLA Fielding School of Public Health, USA
5:00pm – 5:30pm		Theme Speech 4 Cancer Drug Development: From Chemotherapy to Immunotherapy Professor Anthony Chan Associate Dean (External Affairs) The Chinese University of Hong Kong, Hong Kong
5:30pm – 6:00pm		Theme Speech 5 Coaching – Modern Pharmacy Management and Development Mr. Charlie Lang Founder and Managing Partner Progress-U Asia, Hong Kong
6:15 pm – 6:45 pm		Pre-dinner Symposium (sponsored by Otsuka Pharmaceutical (H.K.) Ltd.) The Role of Aquaresis in Heart Failure Dr. Pak-hei Chan Clinical Assistant Professor Department of Medicine The University of Hong Kong, Hong Kong
7:00pm – 10:00pm		Conference Dinner

Programme Rundown

28 February 2016 (Sunday)

Concurrent Session	Room N101A	Room N101B	Room N111-12
	I: Dyslipidaemia	II: Emerging Therapeutics	III: Coaching
	Moderator: Jacky Chung	Moderator: Ritchie Kwok	Moderator: Donald Chong
8:30am – 8:55am	Guidelines Stand-off: Treating your Patients like Americans or Europeans? Professor Hung-fat Tse (Hong Kong)	Next Generation Sequencing to Help Drug Choice Dr. Vivian Lui (Hong Kong)	Coaching – Practical Exercises, Discussion and Case Examples Mr. Charlie Lang (Hong Kong)
8:55am – 9:20am	Statins Intolerance – Evidence, Mechanism, Management. What's More to Say? Professor Brian Tomlinson (Hong Kong)	Nanotechnology-based Therapeutics: Advances and Applications Dr. Ho-wah Hui (USA)	
9:20am – 9:45am	PCSK9-targeted Agents in an Era without Treatment Targets Dr. Hyun-ho Kim (Korea)	Advanced Parkinson's Disease Treatment Update – Pharmacotherapy and Surgical Interventions Professor Vincent Mok (Hong Kong)	
9:45am – 10:00am	Panel Discussion and Q & A		
10:00am – 10:30am	Coffee Break - Poster Presentations & Exhibition		
Concurrent Session	IV: Infectious Disease and Practice	V: Public Private Interface	VI: Advanced Practice
	Moderator: Simon So	Moderator: Andy Wong	Moderator: Philip Kwok
	10:30am – 10:55am	Treatment for MERS-CoV: International and Local Perspectives Dr. Kin-wing Choi (Hong Kong)	Role of Comprehensive Quality Assurance in Medication Safety - a Public Hospital Perspective* Mr. Xue-dong Xu 胥雪冬 (China) <i>(This session will be conducted in Mandarin)</i>
10:55am – 11:20am	The State of Novel Antibiotics Discovery Mr. Raymond Mak (Hong Kong)	PPI Service at the OAH – The Innovative Way! Ms. Sau-chu Chiang (Hong Kong)	
11:20am – 11:30am	Panel Discussion and Q & A		

Programme Rundown

28 February 2016 (Sunday)

Concurrent Session	Room N101A	Room N101B	Room N111-12
	Oral Presentation 1: Practice	Oral Presentation 2: Free Paper	Oral Presentation 3: Regulatory
	Moderator: Simon So	Moderator: Andy Wong	Moderator: Philip Kwok
11:30am – 12:15pm	<p>Nominated projects from Master of Clinical Pharmacy programme</p> <p>1. Clinical Implications of Pharmacist Interventions on Drug Administration for Geriatric Patients with Dysphagia</p> <p>Mr. Andy Chang (Hong Kong)</p> <p>2. A Study on the Impact of a Pharmacist-led Neurology Refill Clinic: Experience of a Local Hospital in Hong Kong</p> <p>Mr. Sam Fong (Hong Kong)</p> <p>3. Evaluation of the Prescribing Pattern and Efficacy of Antiemetic for Chemotherapy-induced Nausea and Vomiting in a Public Hospital</p> <p>Mr. Raymond Chau (Hong Kong)</p> <p>4. A Retrospective Cohort Study Comparing Safety and Efficacy of Proprietary Filgrastim (Neupogen®) versus Biosimilar Filgrastim (Nivestim®) for Primary Prophylaxis of Neutropenia in Patients Receiving Adjuvant or Neo-adjuvant Chemotherapy Treatment for Breast Cancer in a Local Hospital</p> <p>Ms. Florence Ma (Hong Kong)</p> <p>5. An Audit on the Management of Over-anticoagulation in Warfarinised Adult Patients in a Local Public Hospital</p> <p>Ms. Shing-yu Suen (Hong Kong)</p> <p>6. Impact of Pharmacist-conducted Discharge Counselling for Chronic Obstructive Pulmonary Disease (COPD) Patients: A Pilot Study</p> <p>Mr. Peter Yuen (Hong Kong)</p>	<p>1. A Retrospective Study Investigating Effect of Dual versus Monotherapy Inhaled Corticosteroids on Outcomes of Pneumonia among COPD Patients</p> <p>Mr. Ka-ming Ho (Hong Kong)</p> <p>2. Development of an Assessment Tool for the Clinical Significance of Pharmacy Interventions in Pediatric In-Patient Setting</p> <p>Ms. Chui-shan Tsang (Hong Kong)</p> <p>3. Symbol of National Quality (SNQ) - The Innovative Traffic Light-like Model-Dynamic Candidate Drug iSMART Calling System (DCDCS)</p> <p>Mrs. Ya-cheng Lee (Taiwan)</p> <p>4. The Impact of Antibiotic Stewardship Program in Center-Taiwan Hospital: A Segmented Time Series Analysis</p> <p>Mr. Yung-ta Lin (Taiwan)</p> <p>5. Implementation of Pharmacist-managed Medication Review and Reconciliation Service at Orthopaedic Wards in Queen Elizabeth Hospital</p> <p>Ms. Chung-yuet Yu (Hong Kong)</p> <p>6. A Global View of the Pharmacy Dispenser Education and Certification</p> <p>Ms. Windy Chan (Hong Kong)</p>	<p>Nominated projects from Master of Science in Pharmaceutical Manufacturing and Quality programme</p> <p>1. Impact of Excipients on Quality and Safety of Oral Pharmaceutical Products</p> <p>Ms. Sze-ka Ko (Hong Kong)</p> <p>2. Medical Device Legislation in Hong Kong at its Crossroads Regulatory Gap Analysis and Review</p> <p>Ms. Colleen Chan (Hong Kong)</p> <p>3. Implementation of Quality Risk Management in a Hong Kong Pharmaceutical Manufacturer for PIC/S GMP Compliance</p> <p>Ms. Lorita Ho (Hong Kong)</p> <p>4. Risk-based Approach to Evaluate the Quality of Proprietary Chinese Medicine</p> <p>Ms. Rosita Leung (Hong Kong)</p> <p>5. Applying Risk Assessment to Evaluate the Quality Costs in a Local Startup Pharmaceutical Manufacturing Organization</p> <p>Ms. Ho-chi Cham (Hong Kong)</p> <p>6. Pharmacovigilance-Drug Safety Risk Management</p> <p>Ms. Yvonne Chan (Hong Kong)</p>

Programme Rundown

28 February 2016 (Sunday)

Time	Bauhinia Room (Ground Floor, Phase II)		
	Lunch Symposium (sponsored by GlaxoSmithKline)		
	Moderator: Phoebe Chan		
12:15pm – 1:45pm	Update Treatment of Asthma and COPD in 2016 Dr. Siu-pui Lam (Hong Kong)		
Concurrent Session	Room N101A	Room N101B	Room N111-12
	VII: Practice Research	VIII: Drug Formulation and Pharmacokinetics	IX: Biosimilars
	Moderator: Wilson Leung	Moderator: Michael Ling	Moderator: Thomas Lee
1:45pm – 2:10pm	Practice-based Research – The Search for Best Practice that Brings Reliable Results Professor Grace Kuo (USA)	A Scientific and Practical Review of Modified Release Formulations – Splittable, Breakable, Crushable? Professor William Charman (Australia)	Biosimilars: Changes in Global Economic and Local Prescribing Landscape Mr. Colin Hui (Australia)
2:10pm – 2:35pm	Big Data Decision Analytics Professor Helen Meng (Hong Kong)	Missing Doses and Wrong Times: Do They Matter? – Application of Clinical Pharmacokinetics and Pharmacodynamics Concepts Professor Teddy Lam (Hong Kong)	Regulatory and Therapeutic Prospects of Biosimilars Mr. Clive Chan (Hong Kong)
2:35pm – 3:00pm	Research on Medication Safety: How could the Impact of Medicine Safety Policy and Practice be Evaluated? Professor Ian Wong (UK)	Therapeutic Drug Monitoring with Antimicrobials - Extrapolating Science to Practice Ms. Kitty Ng (Hong Kong)	How should Biosimilars be Handled in the Pharmacy Dr. Vivian Lee (Hong Kong)
3:00pm – 3:15pm	Panel Discussion and Q & A		
Time	Room N101A		
	Plenary Session: Pharmacy Council		
	Moderator: Philip Chiu		
3:15pm – 4:15pm	Update from Pre-Pharmacy Council Task Force Task Force Members <i>(This session will be conducted in Cantonese)</i>		
4:15pm – 4:30pm	Closing Remarks Mr. Lot Chan Chairman Organizing Committee of HKPC 2017		